 Lauren Vanderlinden
Concepts (286)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| DNA Methylation | 10 | 2025 | 643 | 2.130 |
Why?
| | Islets of Langerhans | 8 | 2025 | 803 | 1.380 |
Why?
| | Autoimmunity | 10 | 2025 | 908 | 1.180 |
Why?
| | Alcohol Drinking | 6 | 2018 | 828 | 0.980 |
Why?
| | Diabetes Mellitus, Type 1 | 13 | 2025 | 3715 | 0.940 |
Why?
| | Rats, Inbred Strains | 4 | 2019 | 362 | 0.650 |
Why?
| | Lupus Erythematosus, Systemic | 1 | 2022 | 242 | 0.640 |
Why?
| | Quantitative Trait Loci | 5 | 2020 | 380 | 0.630 |
Why?
| | Smoking | 1 | 2025 | 1627 | 0.550 |
Why?
| | Quantitative Trait, Heritable | 2 | 2017 | 125 | 0.550 |
Why?
| | Arthritis, Rheumatoid | 3 | 2024 | 1167 | 0.550 |
Why?
| | Genetic Predisposition to Disease | 8 | 2024 | 2426 | 0.520 |
Why?
| | Gene Regulatory Networks | 4 | 2019 | 305 | 0.510 |
Why?
| | Autoantibodies | 6 | 2024 | 1496 | 0.500 |
Why?
| | Brain | 8 | 2022 | 2668 | 0.500 |
Why?
| | Genome-Wide Association Study | 6 | 2024 | 1431 | 0.490 |
Why?
| | Darkness | 1 | 2015 | 28 | 0.460 |
Why?
| | Glucagon-Like Peptide-1 Receptor | 2 | 2025 | 82 | 0.460 |
Why?
| | Alcoholism | 3 | 2014 | 807 | 0.400 |
Why?
| | Oxylipins | 3 | 2023 | 40 | 0.390 |
Why?
| | Circadian Rhythm | 1 | 2015 | 468 | 0.340 |
Why?
| | Phenotype | 2 | 2015 | 3196 | 0.310 |
Why?
| | Polymorphism, Single Nucleotide | 6 | 2025 | 2189 | 0.310 |
Why?
| | Body Mass Index | 4 | 2025 | 2389 | 0.300 |
Why?
| | Systems Biology | 2 | 2019 | 67 | 0.280 |
Why?
| | Algorithms | 3 | 2024 | 1704 | 0.280 |
Why?
| | Male | 30 | 2025 | 67762 | 0.280 |
Why?
| | CpG Islands | 3 | 2023 | 157 | 0.270 |
Why?
| | Urinary Bladder Neoplasms | 2 | 2021 | 252 | 0.250 |
Why?
| | Child | 16 | 2025 | 21935 | 0.240 |
Why?
| | Genotype | 4 | 2025 | 1916 | 0.240 |
Why?
| | Longitudinal Studies | 4 | 2025 | 2844 | 0.230 |
Why?
| | Diet | 3 | 2021 | 1278 | 0.230 |
Why?
| | Metabolomics | 5 | 2021 | 678 | 0.220 |
Why?
| | Humans | 39 | 2025 | 137585 | 0.220 |
Why?
| | Seroconversion | 2 | 2021 | 46 | 0.220 |
Why?
| | Carnitine O-Palmitoyltransferase | 2 | 2021 | 46 | 0.220 |
Why?
| | Female | 26 | 2025 | 73304 | 0.210 |
Why?
| | Gene Expression Profiling | 4 | 2021 | 1774 | 0.210 |
Why?
| | Mice, Inbred Strains | 2 | 2015 | 409 | 0.210 |
Why?
| | Ethanol | 2 | 2018 | 608 | 0.200 |
Why?
| | Extracellular Matrix | 2 | 2021 | 528 | 0.200 |
Why?
| | Rats | 9 | 2019 | 5647 | 0.200 |
Why?
| | Adiposity | 2 | 2017 | 518 | 0.200 |
Why?
| | Animals | 19 | 2022 | 36940 | 0.190 |
Why?
| | Adolescent | 11 | 2025 | 21513 | 0.190 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 1276 | 0.190 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 313 | 0.180 |
Why?
| | Case-Control Studies | 7 | 2023 | 3556 | 0.180 |
Why?
| | Pregnancy | 6 | 2025 | 6763 | 0.180 |
Why?
| | Epidemiologic Studies | 1 | 2021 | 72 | 0.180 |
Why?
| | Disease Progression | 3 | 2024 | 2757 | 0.180 |
Why?
| | Propensity Score | 1 | 2023 | 294 | 0.180 |
Why?
| | Heart Murmurs | 1 | 2021 | 14 | 0.180 |
Why?
| | Lipid Metabolism | 3 | 2019 | 518 | 0.180 |
Why?
| | Risk Factors | 7 | 2023 | 10388 | 0.170 |
Why?
| | Diabetes, Gestational | 1 | 2025 | 318 | 0.170 |
Why?
| | Vitamins | 1 | 2022 | 185 | 0.170 |
Why?
| | Prenatal Exposure Delayed Effects | 2 | 2025 | 605 | 0.170 |
Why?
| | Hyaluronan Receptors | 1 | 2021 | 102 | 0.170 |
Why?
| | Twins, Monozygotic | 1 | 2021 | 203 | 0.170 |
Why?
| | Diseases in Twins | 1 | 2021 | 169 | 0.170 |
Why?
| | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid | 1 | 2020 | 15 | 0.160 |
Why?
| | Child, Preschool | 10 | 2024 | 11074 | 0.160 |
Why?
| | Infant Nutritional Physiological Phenomena | 1 | 2021 | 146 | 0.160 |
Why?
| | Receptors, Androgen | 1 | 2021 | 150 | 0.160 |
Why?
| | Epigenesis, Genetic | 5 | 2024 | 660 | 0.160 |
Why?
| | Phospholipids | 1 | 2021 | 223 | 0.160 |
Why?
| | Drosophila | 1 | 2020 | 154 | 0.160 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2021 | 767 | 0.160 |
Why?
| | Anthracenes | 1 | 2019 | 31 | 0.160 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2021 | 210 | 0.160 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2019 | 108 | 0.150 |
Why?
| | Fluorenes | 1 | 2019 | 44 | 0.150 |
Why?
| | Eicosanoids | 1 | 2019 | 62 | 0.150 |
Why?
| | Drosophila Proteins | 1 | 2020 | 204 | 0.150 |
Why?
| | Mice | 9 | 2022 | 17787 | 0.150 |
Why?
| | Vitamin D | 1 | 2022 | 397 | 0.150 |
Why?
| | Ventricular Remodeling | 1 | 2021 | 266 | 0.150 |
Why?
| | Scoliosis | 1 | 2021 | 215 | 0.150 |
Why?
| | Hippocampus | 2 | 2022 | 895 | 0.140 |
Why?
| | Metabolic Clearance Rate | 1 | 2018 | 115 | 0.140 |
Why?
| | Unsupervised Machine Learning | 1 | 2018 | 22 | 0.140 |
Why?
| | Alveolar Epithelial Cells | 1 | 2019 | 114 | 0.140 |
Why?
| | Insulin | 4 | 2025 | 2409 | 0.140 |
Why?
| | Endocrine Disruptors | 1 | 2018 | 42 | 0.140 |
Why?
| | Phthalic Acids | 1 | 2018 | 40 | 0.140 |
Why?
| | Central Amygdaloid Nucleus | 1 | 2017 | 3 | 0.140 |
Why?
| | Health Status | 1 | 2023 | 792 | 0.140 |
Why?
| | GABA Modulators | 1 | 2017 | 12 | 0.140 |
Why?
| | CD24 Antigen | 1 | 2017 | 20 | 0.140 |
Why?
| | Fatty Acids | 2 | 2017 | 443 | 0.140 |
Why?
| | Food Hypersensitivity | 1 | 2020 | 183 | 0.140 |
Why?
| | Genetic Association Studies | 2 | 2020 | 377 | 0.130 |
Why?
| | Prospective Studies | 4 | 2023 | 7604 | 0.130 |
Why?
| | Transcriptome | 3 | 2018 | 971 | 0.130 |
Why?
| | Multifactorial Inheritance | 1 | 2018 | 174 | 0.130 |
Why?
| | Insulin Resistance | 1 | 2025 | 1208 | 0.130 |
Why?
| | Dermatitis, Atopic | 1 | 2020 | 329 | 0.130 |
Why?
| | Cross-Sectional Studies | 3 | 2023 | 5472 | 0.130 |
Why?
| | Voltage-Gated Sodium Channels | 1 | 2016 | 5 | 0.130 |
Why?
| | Seizures | 1 | 2020 | 426 | 0.130 |
Why?
| | Maternal Exposure | 1 | 2018 | 190 | 0.130 |
Why?
| | Receptors, GABA-A | 1 | 2017 | 142 | 0.120 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2017 | 197 | 0.120 |
Why?
| | Phenylurea Compounds | 1 | 2016 | 97 | 0.120 |
Why?
| | Anxiety | 1 | 2022 | 1035 | 0.120 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2015 | 17 | 0.120 |
Why?
| | Quinolines | 1 | 2016 | 178 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 1396 | 0.110 |
Why?
| | Microarray Analysis | 1 | 2015 | 117 | 0.110 |
Why?
| | Cohort Studies | 2 | 2022 | 5742 | 0.110 |
Why?
| | Birth Weight | 1 | 2017 | 516 | 0.110 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2015 | 539 | 0.110 |
Why?
| | Neuralgia | 1 | 2016 | 133 | 0.110 |
Why?
| | Receptors, N-Methyl-D-Aspartate | 1 | 2016 | 219 | 0.110 |
Why?
| | Principal Component Analysis | 1 | 2015 | 195 | 0.110 |
Why?
| | Diabetes Mellitus, Type 2 | 3 | 2023 | 2531 | 0.110 |
Why?
| | Obesity | 2 | 2017 | 2992 | 0.110 |
Why?
| | Infant | 7 | 2024 | 9465 | 0.110 |
Why?
| | Cell Nucleus | 1 | 2017 | 620 | 0.110 |
Why?
| | Cell Proliferation | 2 | 2021 | 2475 | 0.100 |
Why?
| | Behavior, Addictive | 1 | 2014 | 81 | 0.100 |
Why?
| | Genetic Variation | 1 | 2019 | 991 | 0.100 |
Why?
| | Molecular Targeted Therapy | 1 | 2016 | 411 | 0.100 |
Why?
| | Species Specificity | 1 | 2014 | 585 | 0.100 |
Why?
| | Adenylyl Cyclases | 1 | 2012 | 87 | 0.100 |
Why?
| | Choice Behavior | 1 | 2014 | 170 | 0.100 |
Why?
| | Gene Expression | 1 | 2017 | 1502 | 0.100 |
Why?
| | Gene Expression Regulation, Developmental | 1 | 2017 | 860 | 0.100 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2012 | 79 | 0.100 |
Why?
| | Pediatrics | 1 | 2020 | 1101 | 0.090 |
Why?
| | Neurons | 2 | 2020 | 1590 | 0.090 |
Why?
| | Ibuprofen | 1 | 2012 | 84 | 0.090 |
Why?
| | Mammary Glands, Animal | 1 | 2012 | 129 | 0.090 |
Why?
| | Placenta | 1 | 2018 | 750 | 0.090 |
Why?
| | Lipocalin 1 | 1 | 2011 | 2 | 0.090 |
Why?
| | Sequence Analysis, RNA | 2 | 2024 | 452 | 0.090 |
Why?
| | Base Sequence | 1 | 2015 | 2181 | 0.090 |
Why?
| | Blastocyst | 1 | 2011 | 48 | 0.090 |
Why?
| | Rats, Sprague-Dawley | 4 | 2020 | 2486 | 0.090 |
Why?
| | Culture Media | 1 | 2011 | 165 | 0.080 |
Why?
| | HLA-DR4 Antigen | 2 | 2021 | 78 | 0.080 |
Why?
| | Aneuploidy | 1 | 2011 | 89 | 0.080 |
Why?
| | HLA-DR3 Antigen | 2 | 2021 | 80 | 0.080 |
Why?
| | Models, Genetic | 1 | 2013 | 600 | 0.080 |
Why?
| | RNA, Long Noncoding | 1 | 2012 | 181 | 0.080 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 2900 | 0.080 |
Why?
| | Pediatric Obesity | 1 | 2017 | 601 | 0.080 |
Why?
| | Liver | 1 | 2018 | 1943 | 0.080 |
Why?
| | Postpartum Period | 1 | 2012 | 340 | 0.080 |
Why?
| | Prenatal Diagnosis | 1 | 2011 | 201 | 0.080 |
Why?
| | Depressive Disorder, Major | 1 | 2012 | 364 | 0.070 |
Why?
| | Sex Factors | 1 | 2015 | 2071 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 3 | 2021 | 532 | 0.070 |
Why?
| | Mice, Nude | 2 | 2021 | 698 | 0.070 |
Why?
| | Tumor Cells, Cultured | 2 | 2021 | 955 | 0.070 |
Why?
| | Proportional Hazards Models | 2 | 2021 | 1266 | 0.070 |
Why?
| | Rats, Inbred BN | 2 | 2018 | 58 | 0.070 |
Why?
| | Asthma | 1 | 2020 | 2295 | 0.070 |
Why?
| | RNA, Messenger | 1 | 2014 | 2833 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2021 | 872 | 0.060 |
Why?
| | Signal Transduction | 1 | 2019 | 5079 | 0.060 |
Why?
| | Monte Carlo Method | 1 | 2024 | 148 | 0.050 |
Why?
| | Glucose Tolerance Test | 1 | 2025 | 366 | 0.050 |
Why?
| | Proteomics | 1 | 2011 | 1111 | 0.050 |
Why?
| | Body Height | 1 | 2024 | 199 | 0.050 |
Why?
| | GTPase-Activating Proteins | 1 | 2023 | 83 | 0.050 |
Why?
| | Colitis, Ulcerative | 1 | 2024 | 136 | 0.050 |
Why?
| | Up-Regulation | 2 | 2019 | 843 | 0.050 |
Why?
| | Polymorphism, Genetic | 1 | 2025 | 660 | 0.050 |
Why?
| | Biological Specimen Banks | 1 | 2023 | 102 | 0.050 |
Why?
| | Ascorbic Acid | 1 | 2023 | 177 | 0.050 |
Why?
| | Epitopes | 1 | 2023 | 479 | 0.050 |
Why?
| | Cell Differentiation | 2 | 2020 | 1991 | 0.050 |
Why?
| | Selection Bias | 1 | 2021 | 37 | 0.040 |
Why?
| | Linoleic Acid | 1 | 2021 | 43 | 0.040 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 8 | 1 | 2021 | 63 | 0.040 |
Why?
| | Photoreceptor Cells, Invertebrate | 1 | 2020 | 4 | 0.040 |
Why?
| | Arachidonic Acid | 1 | 2021 | 120 | 0.040 |
Why?
| | Follow-Up Studies | 2 | 2021 | 5131 | 0.040 |
Why?
| | Glutamate Decarboxylase | 1 | 2021 | 170 | 0.040 |
Why?
| | Prognosis | 2 | 2021 | 4030 | 0.040 |
Why?
| | Docosahexaenoic Acids | 1 | 2021 | 84 | 0.040 |
Why?
| | Probability | 1 | 2021 | 304 | 0.040 |
Why?
| | Colorado | 2 | 2023 | 4565 | 0.040 |
Why?
| | Fatty Acids, Omega-6 | 1 | 2020 | 48 | 0.040 |
Why?
| | Kainic Acid | 1 | 2020 | 35 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2553 | 0.040 |
Why?
| | Bias | 1 | 2021 | 218 | 0.040 |
Why?
| | Body Weight | 1 | 2024 | 985 | 0.040 |
Why?
| | Inflammation | 2 | 2024 | 2837 | 0.040 |
Why?
| | Nerve Tissue Proteins | 1 | 2023 | 596 | 0.040 |
Why?
| | Fetal Blood | 1 | 2021 | 327 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2020 | 195 | 0.040 |
Why?
| | Group IV Phospholipases A2 | 1 | 2019 | 47 | 0.040 |
Why?
| | Fatty Acids, Omega-3 | 1 | 2020 | 140 | 0.040 |
Why?
| | Chimera | 1 | 2019 | 58 | 0.040 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2021 | 597 | 0.040 |
Why?
| | Molecular Weight | 1 | 2019 | 335 | 0.040 |
Why?
| | Precision Medicine | 1 | 2023 | 429 | 0.040 |
Why?
| | Gene Frequency | 1 | 2020 | 521 | 0.040 |
Why?
| | Receptors, AMPA | 1 | 2020 | 141 | 0.040 |
Why?
| | Rats, Transgenic | 1 | 2018 | 19 | 0.040 |
Why?
| | Rats, Inbred SHR | 1 | 2018 | 45 | 0.040 |
Why?
| | Cyclooxygenase 2 | 1 | 2019 | 178 | 0.040 |
Why?
| | Early Diagnosis | 1 | 2019 | 242 | 0.040 |
Why?
| | Interleukins | 1 | 2020 | 250 | 0.040 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 283 | 0.040 |
Why?
| | Whole Genome Sequencing | 1 | 2019 | 160 | 0.040 |
Why?
| | Acetyl-CoA Carboxylase | 1 | 2017 | 33 | 0.030 |
Why?
| | Breast Feeding | 1 | 2021 | 440 | 0.030 |
Why?
| | Radioligand Assay | 1 | 2017 | 48 | 0.030 |
Why?
| | Muscle Cells | 1 | 2017 | 43 | 0.030 |
Why?
| | Electron Transport | 1 | 2017 | 115 | 0.030 |
Why?
| | Pregnancy Trimester, First | 1 | 2018 | 140 | 0.030 |
Why?
| | Collagen | 1 | 2020 | 452 | 0.030 |
Why?
| | Xenopus laevis | 1 | 2017 | 106 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2019 | 810 | 0.030 |
Why?
| | Carnitine | 1 | 2017 | 84 | 0.030 |
Why?
| | Umbilical Cord | 1 | 2017 | 85 | 0.030 |
Why?
| | Models, Animal | 1 | 2019 | 384 | 0.030 |
Why?
| | Mitochondrial Diseases | 1 | 2017 | 91 | 0.030 |
Why?
| | Calcium | 1 | 2023 | 1199 | 0.030 |
Why?
| | Muscle Development | 1 | 2017 | 111 | 0.030 |
Why?
| | Neoplasm Proteins | 1 | 2020 | 434 | 0.030 |
Why?
| | Electronic Health Records | 1 | 2024 | 1069 | 0.030 |
Why?
| | Immunity, Innate | 1 | 2022 | 828 | 0.030 |
Why?
| | Protein Subunits | 1 | 2017 | 239 | 0.030 |
Why?
| | Sodium Channel Blockers | 1 | 2016 | 24 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2019 | 1272 | 0.030 |
Why?
| | Cricetulus | 1 | 2016 | 109 | 0.030 |
Why?
| | CHO Cells | 1 | 2016 | 161 | 0.030 |
Why?
| | Lymphatic Metastasis | 1 | 2017 | 352 | 0.030 |
Why?
| | Cricetinae | 1 | 2016 | 289 | 0.030 |
Why?
| | Infant, Newborn | 2 | 2017 | 6079 | 0.030 |
Why?
| | Maternal Nutritional Physiological Phenomena | 1 | 2017 | 176 | 0.030 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2017 | 198 | 0.030 |
Why?
| | Neoplasm Invasiveness | 1 | 2017 | 510 | 0.030 |
Why?
| | Databases, Nucleic Acid | 1 | 2015 | 34 | 0.030 |
Why?
| | Blood Glucose | 1 | 2025 | 2186 | 0.030 |
Why?
| | Protein Isoforms | 1 | 2016 | 404 | 0.030 |
Why?
| | Phosphorylation | 1 | 2019 | 1759 | 0.030 |
Why?
| | Protein Conformation | 1 | 2017 | 934 | 0.030 |
Why?
| | Recombination, Genetic | 1 | 2015 | 204 | 0.030 |
Why?
| | Rats, Wistar | 1 | 2015 | 455 | 0.030 |
Why?
| | Binding Sites | 1 | 2017 | 1303 | 0.030 |
Why?
| | Amino Acids | 1 | 2017 | 497 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2017 | 1060 | 0.030 |
Why?
| | Software | 1 | 2019 | 665 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2016 | 730 | 0.030 |
Why?
| | Cell Line | 1 | 2019 | 2847 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2021 | 2828 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2017 | 1389 | 0.030 |
Why?
| | Biomarkers | 2 | 2017 | 4149 | 0.030 |
Why?
| | Lipids | 1 | 2017 | 672 | 0.030 |
Why?
| | Basement Membrane | 1 | 2012 | 35 | 0.020 |
Why?
| | Survival Rate | 1 | 2017 | 1972 | 0.020 |
Why?
| | Protein Interaction Maps | 1 | 2012 | 48 | 0.020 |
Why?
| | Laminin | 1 | 2012 | 72 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2016 | 496 | 0.020 |
Why?
| | Models, Molecular | 1 | 2017 | 1570 | 0.020 |
Why?
| | Spectrometry, Mass, Electrospray Ionization | 1 | 2012 | 180 | 0.020 |
Why?
| | Adult | 3 | 2021 | 37929 | 0.020 |
Why?
| | Energy Metabolism | 1 | 2017 | 922 | 0.020 |
Why?
| | Embryo Culture Techniques | 1 | 2011 | 11 | 0.020 |
Why?
| | Extracellular Matrix Proteins | 1 | 2012 | 153 | 0.020 |
Why?
| | Mothers | 1 | 2017 | 754 | 0.020 |
Why?
| | Young Adult | 2 | 2018 | 13209 | 0.020 |
Why?
| | Haplotypes | 1 | 2012 | 494 | 0.020 |
Why?
| | Mitochondria | 1 | 2017 | 948 | 0.020 |
Why?
| | Oxidative Stress | 1 | 2017 | 1317 | 0.020 |
Why?
| | RNA | 1 | 2017 | 921 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2017 | 1164 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 345 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2021 | 4295 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1793 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 7635 | 0.020 |
Why?
| | Chromatography, Liquid | 1 | 2011 | 433 | 0.020 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 852 | 0.020 |
Why?
| | Gene Expression Regulation | 1 | 2017 | 2607 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 6828 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2020 | 5778 | 0.020 |
Why?
| | Predictive Value of Tests | 1 | 2011 | 2031 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2012 | 4193 | 0.010 |
Why?
| | Aged | 1 | 2023 | 23961 | 0.010 |
Why?
|
|
Vanderlinden's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|